The molecular cytogenetics market is anticipated to grow significantly in the North American area as a result of enhanced healthcare infrastructure, effective government policies, a huge base of multinational firms, and an increase in genetic disorders. The Indiana Health Coverage Programme module covers chromosomal microarray analysis (CMA), also known as cytogenetic microarray analysis, which is determined to be medically necessary for diagnosing a genetic abnormality in children with apparent nonsyndromic cognitive developmental delay/intellectual delay (DD/ID) or autism spectrum disorder (ASD), according to the article published in May 2022.
The market for Molecular Cytogenetics is anticipated to reach US$ 4,211.4 million in 2023 and is projected to grow at a CAGR of 24.5% from 2023 to 2030.
Major Players in the Molecular Cytogenetics Industry:
Abbott Laboratories:
1. Abbott produces and sells branded generic pharmaceuticals, adult and paediatric nutritional items, diagnostic tools, and testing kits. Pacemakers, implanted cardioverter defibrillators, neuromodulation tools, coronary stents, catheters, baby formula, adult dietary liquids, molecular diagnostic platforms, immunoassays, and point-of-care diagnostic tools are among the products. Built in 1888. American headquarters in North Chicago. Recent Acquisitions: Cephea Valve Technologies (Jan 2019), JETi (Sep 2021), Cardiovascular Systems (Feb 2023).
Agilent Technologies, Inc.:
2. Agilent, which was first separated from Hewlett-Packard in 1999, has grown into a major player in the life sciences and diagnostics industries. With its three operating segments—life science and applied tools, cross lab (containing of consumables and services connected to life science and applied tools), and diagnostics and genomics—Agilent's measuring solutions currently serve a wide range of clients. The most recent acquisitions include Resolution Bioscience (Mar 2021), PSS Polymer Standards Service (Aug 2022), and Avida Biomed (Jan 2023).